The Rutland Hospital Inc. of Rutland, Vermont and the four community Oncologists practicing in Vermont have formed a consortium for the purposes of establishing a cooperative cancer control and clinical research program in a rural area. The Green Mountain Oncology Group (GMOG) will join with the Vermont Regional Cancer Center (VRCC) for the purposes of: 1. Developing and participating in high priority Phase II, Phase III, and adjuvant treatment clinical trial protocols of the NSABP, ECOG and VRCC. 2. Providing the administrative, oncology nursing and data management support so that the practicing oncologists and primary care physicians can participate effectively in these clinical trials. 3. Providing a quality control system to assure complete and accurate data collection. 4. Providing for the analysis, presentation, and publication of the results of the clinical trials. 5. Further developing and refining cancer control activities which will measurably improve the quality of cancer care provided in the region. 6. Expanding the GMOG by assisting oncologists and hospitals in the region to formalize clinical research and cancer control programs. 7. Serving as a model for development of the rural community hospital oncology program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035091-03
Application #
3557459
Study Section
(SRC)
Project Start
1983-09-30
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Rutland Regional Medical Center
Department
Type
DUNS #
City
Rutland
State
VT
Country
United States
Zip Code
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Demmy, Todd L; Gu, Lin; Burkhalter, Jack E et al. (2012) Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw 10:975-82
Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247-53
Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32
Rocha-Lima, C M; Herndon 2nd, J E; Lee, M E et al. (2007) Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 18:331-7
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6
Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81
Bogart, Jeffrey A; Herndon 2nd, James E; Lyss, Alan P et al. (2004) 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 59:460-8

Showing the most recent 10 out of 18 publications